The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...

Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit won’t be answered until Phase 3 tests read out.

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on ...

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein(a), or lp(a), met its primary endpoint, reducing lp(a) levels by an average of 93.9% over ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a mid-stage clinical trial involving 141 patients. Lp(a) is a genetic risk factor ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated 1.4 billion people worldwide, including 64 million people in the U.S.

Positive early stage data for Verve Therapeutics Inc.’s base editing therapy points to a range of development options, ...

Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments. The company reported strong financial results, with significant ...